Cancer Research and Treatment

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova, Xavier Pivot

Clinical Breast Cancer.2022; 22(3): 223. CrossRef

Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future

Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck

Cancer Treatment Reviews.2022; 102: 102321. CrossRef

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Zhi-Ming Shao, Yi-Zhou Jiang

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival

F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci, V. Guarneri

Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class

Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, S

Breast Cancer Research and Treatment.2022;[Epub] CrossRef

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Picc

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders

Breast Cancer Research and Treatment.2021; 185(3): 759. CrossRef

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab,

New England Journal of Medicine.2021; 384(16): 1529. CrossRef

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset H

Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report

Angelats L, Estival A, Martinez-Cardús A, Musulen E, Margelí M

Current Problems in Cancer: Case Reports.2021; : 100097. CrossRef

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo

Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies

Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife

High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer

Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Jörg Paul Weimer, Christoph Rogmans, Marion T. van Mackelenbergh, Nicolai Maass, Bernd Clement, Dirk O. Bauerschlag

Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center

Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer

Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan

New England Journal of Medicine.2019; 380(8): 741. CrossRef

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine

I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen

Cancer Chemotherapy and Pharmacology.2019; 84(2): 441. CrossRef

Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar

Expert Review of Anticancer Therapy.2019; 19(7): 589. CrossRef

Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond

Expert Review of Anticancer Therapy.2019; 19(8): 673. CrossRef

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer

Journal of Modern Oncology.2018; 20(3): 26. CrossRef